Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
Clinical Trial Evaluating the Safety and Activity of Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
Sponsor: Changhai Hospital
A PHASE1/PHASE2 clinical study on Advanced Cancer and Pancreatic Cancer, this trial is actively recruiting participants. The trial is conducted by Changhai Hospital and has accumulated 14 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
14 versions recorded-
Jan 2026 — Present [monthly]
Recruiting PHASE1/PHASE2
Status: Unknown → Recruiting
-
Oct 2025 — Jan 2026 [monthly]
Unknown PHASE1/PHASE2
Status: Recruiting → Unknown
-
Sep 2024 — Oct 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 9 earlier versions
-
Jul 2022 — Oct 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2022 — Jul 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2021 — Mar 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — Jun 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2020 — Oct 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2020 — Jun 2020 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Dec 2019 — Feb 2020 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Nov 2019 — Dec 2019 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Changhai Hospital
For direct contact, visit the study record on ClinicalTrials.gov .